Diindolylmethane in Preventing Cancer in Healthy Volunteers
Ključne riječi
Sažetak
Opis
PRIMARY OBJECTIVES:
I. To determine single oral doses of 3,3' di-indolylmethane (DIM) (diindolylmethane) that are safe and well- tolerated.
II. To determine the pharmacokinetics of these single oral doses of DIM.
OUTLINE: This is a dose-escalation study. Participants are randomized to 1 of 2 treatment arms.
ARM I: Participants receive a single dose of diindolylmethane orally (PO) on day 1.
ARM II: Participants receive a single dose of placebo orally (PO) on day 1.
After completion of study treatment, participants are followed up on days 2, 3, and 6.
Datumi
Posljednja provjera: | 11/30/2016 |
Prvo podneseno: | 10/31/2008 |
Predviđena prijava poslana: | 10/31/2008 |
Prvo objavljeno: | 11/03/2008 |
Posljednje ažuriranje poslano: | 12/27/2016 |
Posljednje ažuriranje objavljeno: | 12/28/2016 |
Stvarni datum početka studija: | 03/31/2004 |
Procijenjeni datum primarnog završetka: | 09/30/2009 |
Procijenjeni datum završetka studije: | 09/30/2009 |
Stanje ili bolest
Intervencija / liječenje
Drug: Arm I (diindolylmethane)
Other: Arm II (placebo)
Other: pharmacological study
Other: laboratory biomarker analysis
Other: quality-of-life assessment
Faza
Grupe ruku
Ruka | Intervencija / liječenje |
---|---|
Experimental: Arm I (diindolylmethane) Participants receive a single dose of diindolylmethane PO on day 1. | Drug: Arm I (diindolylmethane) Given PO |
Placebo Comparator: Arm II (placebo) Participants receive a single dose of placebo orally (PO) on day 1. | Other: Arm II (placebo) Given PO |
Kriterij prihvatljivosti
Dobni uvjeti za studiranje | 18 Years Do 18 Years |
Spolovi koji ispunjavaju uvjete za studij | All |
Prihvaća zdrave volontere | Da |
Kriteriji | Inclusion Criteria: - Non-smokers and non-users of abuse drugs as confirmed by urine cotinine (Accutest NicoMeter Urine Professional strip or equivalent test) and drug screen at visit 1 - Free of acute, unstable, chronic or recurring medical conditions based on history, physical examination, laboratory tests; the laboratory tests to be performed will be: blood serum chemistry screen to include comprehensive metabolic panel (glucose, creatinine, urea nitrogen [blood urea nitrogen (BUN)], sodium, potassium, chloride, calcium, total bilirubin, protein, albumin, globulin, cholesterol and the enzymes alkaline phosphatase, aspartate aminotransferase [AST], and alanine aminotransferase [ALT]) and lipid panel (total, low density lipoprotein [LDL] and high density lipoprotein [HDL] cholesterol and triglycerides); complete blood count including differential and platelet count; prothrombin time; and routine urinalysis; values for laboratory tests must be within the ranges below grade 2 of Common Toxicity Criteria (CTC) and/or as specified below: - Hemoglobin > 10 g/dL - Absolute granulocyte count > 1500/ìL - Creatinine < 2.0 mg/dl - Albumin > 3.0 g/dl - Bilirubin < 1.8 mg/dl - AST < 110 U/l - ALT < 110 U/l - Alkaline phosphatase < 300 U/l - Subjects must weigh +/- 20% of ideal body weight by the Metropolitan Life tables - Men or women who are strict vegetarians or who eat more than 3 medium servings (1/2 cup each) of cruciferous vegetables per week will be excluded; those who stop ingesting cruciferous vegetables >= 14 days and alcohol >= 7 days before starting DIM and agree to refrain from taking them for the duration of the study will not be excluded; cruciferous vegetables include broccoli, cabbage (including coleslaw), cauliflower, bok-choy, Brussels sprouts, collards, kale, kohlrabi, mustard greens, rutabaga, turnip, and watercress; participants will be asked to complete a brief diet questionnaire listing these vegetables to assess these criteria; caffeine- and grapefruit-containing foods and beverages are to be avoided for at least 48 hours before visit 2 (DIM dosing) Exclusion Criteria: - Subjects with serious drug allergies or other serious intolerance or allergies will be excluded; those with mild seasonal allergies will be accepted - Subjects with chronic headaches, dysphoria, fatigue, dizziness, blurred vision, insomnia, rhinorrhea, nausea, vomiting, abdominal pain, diarrhea, constipation, or similar conditions - Subjects with a serious acute or chronic illness (diabetes, arthritis, asthma, etc.) or requiring chronic drug therapy, who continuously take supplements or have taken an investigational drug within the past three months - Subjects who have evidence of an active malignancy or have received chemotherapy, and/or antiestrogen therapy - Subjects who have a life expectancy of < 12 months - Subjects who have regularly taken over the past 21 days any concomitant medications, herbal products, dietary supplements or vitamins; women taking oral contraceptives will be accepted; women who are pregnant (positive urine human chorionic gonadotropin [hCG] at visit 2) or lactating will be excluded |
Ishod
Primarne mjere ishoda
1. Maximum tolerated dose (MTD), defined as the highest dose at which no grade 2 or higher toxicities are seen [Up to day 6]
Sekundarne mjere ishoda
1. Pharmacokinetics of diindolylmethane [Baseline and at 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours after administration]